Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 1616 entries
Sorted by: Best Match Show Resources per page
Stability of glucagon-like peptide 1 and glucagon in human plasma.

Endocrine connections

Wewer Albrechtsen NJ, Bak MJ, Hartmann B, Christensen LW, Kuhre RE, Deacon CF, Holst JJ.
PMID: 25596009
Endocr Connect. 2015 Mar;4(1):50-7. doi: 10.1530/EC-14-0126. Epub 2015 Jan 16.

To investigate the stability of glucagon-like peptide 1 (GLP-1) and glucagon in plasma under short- and long-term storage conditions. Pooled human plasma (n=20), to which a dipeptidyl peptidase 4 (DPP4) inhibitor and aprotinin were added, was spiked with synthetic...

Cite
Wewer Albrechtsen NJ, Bak MJ, Hartmann B, et al. Stability of glucagon-like peptide 1 and glucagon in human plasma. Endocr Connect. 2015;4(1):50-7doi: 10.1530/EC-14-0126.
Wewer Albrechtsen, N. J., Bak, M. J., Hartmann, B., Christensen, L. W., Kuhre, R. E., Deacon, C. F., & Holst, J. J. (2015). Stability of glucagon-like peptide 1 and glucagon in human plasma. Endocrine connections, 4(1), 50-7. https://doi.org/10.1530/EC-14-0126
Wewer Albrechtsen, Nicolai J, et al. "Stability of glucagon-like peptide 1 and glucagon in human plasma." Endocrine connections vol. 4,1 (2015): 50-7. doi: https://doi.org/10.1530/EC-14-0126
Wewer Albrechtsen NJ, Bak MJ, Hartmann B, Christensen LW, Kuhre RE, Deacon CF, Holst JJ. Stability of glucagon-like peptide 1 and glucagon in human plasma. Endocr Connect. 2015 Mar;4(1):50-7. doi: 10.1530/EC-14-0126. Epub 2015 Jan 16. PMID: 25596009; PMCID: PMC4317691.
Copy Download .nbib Format: NLM
Reduced heart function predicts drug-taking compliance and two-year prognosis in chinese patients with stable premature coronary artery disease.

Journal of clinical medicine research

Chen Z, Ding Z, Wang X, Zhang X, Ma G.
PMID: 25584100
J Clin Med Res. 2015 Mar;7(3):154-60. doi: 10.14740/jocmr2045w. Epub 2014 Dec 29.

BACKGROUND: The purpose of this study was to determine the association between heart function, compliance with drug administration, and the mid-term prognosis in Chinese patients with stable premature coronary artery disease (CAD) (male < 55 years and female <...

Cite
Chen Z, Ding Z, Wang X, et al. Reduced heart function predicts drug-taking compliance and two-year prognosis in chinese patients with stable premature coronary artery disease. J Clin Med Res. 2014;7(3):154-60doi: 10.14740/jocmr2045w.
Chen, Z., Ding, Z., Wang, X., Zhang, X., & Ma, G. (2015). Reduced heart function predicts drug-taking compliance and two-year prognosis in chinese patients with stable premature coronary artery disease. Journal of clinical medicine research, 7(3), 154-60. https://doi.org/10.14740/jocmr2045w
Chen, Zhong, et al. "Reduced heart function predicts drug-taking compliance and two-year prognosis in chinese patients with stable premature coronary artery disease." Journal of clinical medicine research vol. 7,3 (2015): 154-60. doi: https://doi.org/10.14740/jocmr2045w
Chen Z, Ding Z, Wang X, Zhang X, Ma G. Reduced heart function predicts drug-taking compliance and two-year prognosis in chinese patients with stable premature coronary artery disease. J Clin Med Res. 2015 Mar;7(3):154-60. doi: 10.14740/jocmr2045w. Epub 2014 Dec 29. PMID: 25584100; PMCID: PMC4285061.
Copy Download .nbib Format: NLM
A Single-Center, Open-Label, Randomized, Parallel-Group Study Assessing the Differences Between an Angiotensin II Receptor Antagonist and an Angiotensin-Converting Enzyme Inhibitor in Hypertensive Patients with Congestive Heart Failure: The Research for Efficacy of Angiotensin II Receptor Antagonist in Hypertensive Patients with Congestive Heart Failure Study.

Current therapeutic research, clinical and experimental

Totsuka N, Awata N, Takahashi K, Yamamura H, Nakamura J, Tsuchikane E, Kobayashi Y, Nishibe A, Terai K.
PMID: 24944358
Curr Ther Res Clin Exp. 2003 Feb;64(2):81-94. doi: 10.1016/S0011-393X(03)00020-1.

BACKGROUND: Angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) have been used to treat congestive heart failure (CHF). According to a MEDLINE search, however, few studies are available on the clinical differences between ARBs and ACEIs in...

Cite
Totsuka N, Awata N, Takahashi K, et al. A Single-Center, Open-Label, Randomized, Parallel-Group Study Assessing the Differences Between an Angiotensin II Receptor Antagonist and an Angiotensin-Converting Enzyme Inhibitor in Hypertensive Patients with Congestive Heart Failure: The Research for Efficacy of Angiotensin II Receptor Antagonist in Hypertensive Patients with Congestive Heart Failure Study. Curr Ther Res Clin Exp. 2003;64(2):81-94doi: 10.1016/S0011-393X(03)00020-1.
Totsuka, N., Awata, N., Takahashi, K., Yamamura, H., Nakamura, J., Tsuchikane, E., Kobayashi, Y., Nishibe, A., & Terai, K. (2003). A Single-Center, Open-Label, Randomized, Parallel-Group Study Assessing the Differences Between an Angiotensin II Receptor Antagonist and an Angiotensin-Converting Enzyme Inhibitor in Hypertensive Patients with Congestive Heart Failure: The Research for Efficacy of Angiotensin II Receptor Antagonist in Hypertensive Patients with Congestive Heart Failure Study. Current therapeutic research, clinical and experimental, 64(2), 81-94. https://doi.org/10.1016/S0011-393X(03)00020-1
Totsuka, Nobuo, et al. "A Single-Center, Open-Label, Randomized, Parallel-Group Study Assessing the Differences Between an Angiotensin II Receptor Antagonist and an Angiotensin-Converting Enzyme Inhibitor in Hypertensive Patients with Congestive Heart Failure: The Research for Efficacy of Angiotensin II Receptor Antagonist in Hypertensive Patients with Congestive Heart Failure Study." Current therapeutic research, clinical and experimental vol. 64,2 (2003): 81-94. doi: https://doi.org/10.1016/S0011-393X(03)00020-1
Totsuka N, Awata N, Takahashi K, Yamamura H, Nakamura J, Tsuchikane E, Kobayashi Y, Nishibe A, Terai K. A Single-Center, Open-Label, Randomized, Parallel-Group Study Assessing the Differences Between an Angiotensin II Receptor Antagonist and an Angiotensin-Converting Enzyme Inhibitor in Hypertensive Patients with Congestive Heart Failure: The Research for Efficacy of Angiotensin II Receptor Antagonist in Hypertensive Patients with Congestive Heart Failure Study. Curr Ther Res Clin Exp. 2003 Feb;64(2):81-94. doi: 10.1016/S0011-393X(03)00020-1. PMID: 24944358; PMCID: PMC4053004.
Copy Download .nbib Format: NLM
Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors.

Acta pharmaceutica Sinica. B

Siklos M, BenAissa M, Thatcher GR.
PMID: 26713267
Acta Pharm Sin B. 2015 Nov;5(6):506-19. doi: 10.1016/j.apsb.2015.08.001. Epub 2015 Sep 26.

Cysteine proteases continue to provide validated targets for treatment of human diseases. In neurodegenerative disorders, multiple cysteine proteases provide targets for enzyme inhibitors, notably caspases, calpains, and cathepsins. The reactive, active-site cysteine provides specificity for many inhibitor designs over...

Cite
Siklos M, BenAissa M, Thatcher GR. Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors. Acta Pharm Sin B. 2015;5(6):506-19doi: 10.1016/j.apsb.2015.08.001.
Siklos, M., BenAissa, M., & Thatcher, G. R. (2015). Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors. Acta pharmaceutica Sinica. B, 5(6), 506-19. https://doi.org/10.1016/j.apsb.2015.08.001
Siklos, Marton, et al. "Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors." Acta pharmaceutica Sinica. B vol. 5,6 (2015): 506-19. doi: https://doi.org/10.1016/j.apsb.2015.08.001
Siklos M, BenAissa M, Thatcher GR. Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors. Acta Pharm Sin B. 2015 Nov;5(6):506-19. doi: 10.1016/j.apsb.2015.08.001. Epub 2015 Sep 26. PMID: 26713267; PMCID: PMC4675809.
Copy Download .nbib Format: NLM
Antihypertensive drug prescription pattern before and during pregnancy in France.

Pregnancy hypertension

Duhalde V, Delarue C, Lacroix I, Suarez C, Bourrel R, Montastruc JL, Damase-Michel C.
PMID: 26104501
Pregnancy Hypertens. 2011 Apr;1(2):185-9. doi: 10.1016/j.preghy.2011.01.001. Epub 2011 Feb 01.

OBJECTIVE: This study provides firsthand information on antihypertensive prescriptions before and during pregnancy in France.METHODS: The study, on 23,898 women, was carried out using data from the French Health Insurance System.RESULTS: Before and during pregnancy, 1.1% and 5.1% of...

Cite
Duhalde V, Delarue C, Lacroix I, et al. Antihypertensive drug prescription pattern before and during pregnancy in France. Pregnancy Hypertens. 2011;1(2):185-9doi: 10.1016/j.preghy.2011.01.001.
Duhalde, V., Delarue, C., Lacroix, I., Suarez, C., Bourrel, R., Montastruc, J. L., & Damase-Michel, C. (2011). Antihypertensive drug prescription pattern before and during pregnancy in France. Pregnancy hypertension, 1(2), 185-9. https://doi.org/10.1016/j.preghy.2011.01.001
Duhalde, Veronique, et al. "Antihypertensive drug prescription pattern before and during pregnancy in France." Pregnancy hypertension vol. 1,2 (2011): 185-9. doi: https://doi.org/10.1016/j.preghy.2011.01.001
Duhalde V, Delarue C, Lacroix I, Suarez C, Bourrel R, Montastruc JL, Damase-Michel C. Antihypertensive drug prescription pattern before and during pregnancy in France. Pregnancy Hypertens. 2011 Apr;1(2):185-9. doi: 10.1016/j.preghy.2011.01.001. Epub 2011 Feb 01. PMID: 26104501.
Copy Download .nbib Format: NLM
Hepatocellular Carcinoma: Basic and Transitional Research.

Gastrointestinal tumors

Yin C, Xie WF.
PMID: 26675991
Gastrointest Tumors. 2014 Jun;1(2):76-83. doi: 10.1159/000362579. Epub 2014 May 09.

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. The outcome of HCC therapy depends on the stage of HCC. Early-stage HCC patients can be cured with radical treatment approaches, whereas no standard treatment...

Cite
Yin C, Xie WF. Hepatocellular Carcinoma: Basic and Transitional Research. Gastrointest Tumors. 2014;1(2):76-83doi: 10.1159/000362579.
Yin, C., & Xie, W. F. (2014). Hepatocellular Carcinoma: Basic and Transitional Research. Gastrointestinal tumors, 1(2), 76-83. https://doi.org/10.1159/000362579
Yin, Chuan, and Xie, Wei-Fen. "Hepatocellular Carcinoma: Basic and Transitional Research." Gastrointestinal tumors vol. 1,2 (2014): 76-83. doi: https://doi.org/10.1159/000362579
Yin C, Xie WF. Hepatocellular Carcinoma: Basic and Transitional Research. Gastrointest Tumors. 2014 Jun;1(2):76-83. doi: 10.1159/000362579. Epub 2014 May 09. PMID: 26675991; PMCID: PMC4645578.
Copy Download .nbib Format: NLM
Small Molecule Docking Supports Broad and Narrow Spectrum Potential for the Inhibition of the Novel Antibiotic Target Bacterial Pth1.

Antibiotics (Basel, Switzerland)

Ferguson PP, Holloway WB, Setzer WN, McFeeters H, McFeeters RL.
PMID: 27171117
Antibiotics (Basel). 2016 May 10;5(2). doi: 10.3390/antibiotics5020016.

Peptidyl-tRNA hydrolases (Pths) play ancillary yet essential roles in protein biosynthesis by recycling peptidyl-tRNA. In E. coli, inhibition of bacterial Pth1 leads to accumulation of peptidyl-tRNA, depletion of aminoacyl-tRNA, and cell death. Eukaryotes have multiple Pths and Pth1 knock...

Cite
Ferguson PP, Holloway WB, Setzer WN, et al. Small Molecule Docking Supports Broad and Narrow Spectrum Potential for the Inhibition of the Novel Antibiotic Target Bacterial Pth1. Antibiotics (Basel). 2016;5(2)doi: 10.3390/antibiotics5020016.
Ferguson, P. P., Holloway, W. B., Setzer, W. N., McFeeters, H., & McFeeters, R. L. (2016). Small Molecule Docking Supports Broad and Narrow Spectrum Potential for the Inhibition of the Novel Antibiotic Target Bacterial Pth1. Antibiotics (Basel, Switzerland), 5(2), . https://doi.org/10.3390/antibiotics5020016
Ferguson, Paul P, et al. "Small Molecule Docking Supports Broad and Narrow Spectrum Potential for the Inhibition of the Novel Antibiotic Target Bacterial Pth1." Antibiotics (Basel, Switzerland) vol. 5,2 (2016). doi: https://doi.org/10.3390/antibiotics5020016
Ferguson PP, Holloway WB, Setzer WN, McFeeters H, McFeeters RL. Small Molecule Docking Supports Broad and Narrow Spectrum Potential for the Inhibition of the Novel Antibiotic Target Bacterial Pth1. Antibiotics (Basel). 2016 May 10;5(2). doi: 10.3390/antibiotics5020016. PMID: 27171117; PMCID: PMC4929431.
Copy Download .nbib Format: NLM
Is kidney function affecting the management of myocardial infarction? A retrospective cohort study in patients with normal kidney function, chronic kidney disease stage III-V, and ESRD.

International journal of nephrology and renovascular disease

Saad M, Karam B, Faddoul G, Douaihy YE, Yacoub H, Baydoun H, Boumitri C, Barakat I, Saifan C, El-Charabaty E, Sayegh SE.
PMID: 26858529
Int J Nephrol Renovasc Dis. 2016 Jan 22;9:5-10. doi: 10.2147/IJNRD.S91567. eCollection 2016.

Patients with chronic kidney disease (CKD) are three times more likely to have myocardial infarction (MI) and suffer from increased morbidity and higher mortality. Traditional and unique risk factors are prevalent and constitute challenges for the standard of care....

Cite
Saad M, Karam B, Faddoul G, et al. Is kidney function affecting the management of myocardial infarction? A retrospective cohort study in patients with normal kidney function, chronic kidney disease stage III-V, and ESRD. Int J Nephrol Renovasc Dis. 2016;9:5-10doi: 10.2147/IJNRD.S91567.
Saad, M., Karam, B., Faddoul, G., Douaihy, Y. E., Yacoub, H., Baydoun, H., Boumitri, C., Barakat, I., Saifan, C., El-Charabaty, E., & Sayegh, S. E. (2016). Is kidney function affecting the management of myocardial infarction? A retrospective cohort study in patients with normal kidney function, chronic kidney disease stage III-V, and ESRD. International journal of nephrology and renovascular disease, 95-10. https://doi.org/10.2147/IJNRD.S91567
Saad, Marc, et al. "Is kidney function affecting the management of myocardial infarction? A retrospective cohort study in patients with normal kidney function, chronic kidney disease stage III-V, and ESRD." International journal of nephrology and renovascular disease vol. 9 (2016): 5-10. doi: https://doi.org/10.2147/IJNRD.S91567
Saad M, Karam B, Faddoul G, Douaihy YE, Yacoub H, Baydoun H, Boumitri C, Barakat I, Saifan C, El-Charabaty E, Sayegh SE. Is kidney function affecting the management of myocardial infarction? A retrospective cohort study in patients with normal kidney function, chronic kidney disease stage III-V, and ESRD. Int J Nephrol Renovasc Dis. 2016 Jan 22;9:5-10. doi: 10.2147/IJNRD.S91567. eCollection 2016. PMID: 26858529; PMCID: PMC4730996.
Copy Download .nbib Format: NLM
Takotsubo Cardiomyopathy: Case Series and Literature Review.

Cureus

Chlus N, Cavayero C, Kar P, Kar S.
PMID: 27446769
Cureus. 2016 Jun 20;8(6):e649. doi: 10.7759/cureus.649.

Although originally considered to be uncommon, Takotsubo cardiomyopathy is becoming increasingly visible, annually comprising an increasing portion of suspected diagnoses of acute coronary syndrome. This condition is characterized by reversible left ventricular akinesis without significant coronary artery obstruction. This...

Cite
Chlus N, Cavayero C, Kar P, et al. Takotsubo Cardiomyopathy: Case Series and Literature Review. Cureus. 2016;8(6):e649doi: 10.7759/cureus.649.
Chlus, N., Cavayero, C., Kar, P., & Kar, S. (2016). Takotsubo Cardiomyopathy: Case Series and Literature Review. Cureus, 8(6), e649. https://doi.org/10.7759/cureus.649
Chlus, Natalie, et al. "Takotsubo Cardiomyopathy: Case Series and Literature Review." Cureus vol. 8,6 (2016): e649. doi: https://doi.org/10.7759/cureus.649
Chlus N, Cavayero C, Kar P, Kar S. Takotsubo Cardiomyopathy: Case Series and Literature Review. Cureus. 2016 Jun 20;8(6):e649. doi: 10.7759/cureus.649. PMID: 27446769; PMCID: PMC4954750.
Copy Download .nbib Format: NLM
Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX.

ACS medicinal chemistry letters

Hutchinson JH, Rowbottom MW, Lonergan D, Darlington J, Prodanovich P, King CD, Evans JF, Bain G.
PMID: 28435530
ACS Med Chem Lett. 2017 Mar 01;8(4):423-427. doi: 10.1021/acsmedchemlett.7b00014. eCollection 2017 Apr 13.

Two series of novel LOXL2 enzyme inhibitors are described: benzylamines substituted with electron withdrawing groups at the

Cite
Hutchinson JH, Rowbottom MW, Lonergan D, et al. Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX. ACS Med Chem Lett. 2017;8(4):423-427doi: 10.1021/acsmedchemlett.7b00014.
Hutchinson, J. H., Rowbottom, M. W., Lonergan, D., Darlington, J., Prodanovich, P., King, C. D., Evans, J. F., & Bain, G. (2017). Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX. ACS medicinal chemistry letters, 8(4), 423-427. https://doi.org/10.1021/acsmedchemlett.7b00014
Hutchinson, John H, et al. "Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX." ACS medicinal chemistry letters vol. 8,4 (2017): 423-427. doi: https://doi.org/10.1021/acsmedchemlett.7b00014
Hutchinson JH, Rowbottom MW, Lonergan D, Darlington J, Prodanovich P, King CD, Evans JF, Bain G. Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX. ACS Med Chem Lett. 2017 Mar 01;8(4):423-427. doi: 10.1021/acsmedchemlett.7b00014. eCollection 2017 Apr 13. PMID: 28435530; PMCID: PMC5392766.
Copy Download .nbib Format: NLM
A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals.

Pathogens & immunity

Cockerham LR, Yukl SA, Harvill K, Somsouk M, Joshi SK, Sinclair E, Liegler T, Hoh R, Lyons S, Hunt PW, Rupert A, Sereti I, Morcock DR, Rhodes A, Emson C, Hellerstein MK, Estes JD, Lewin S, Deeks SG, Hatano H.
PMID: 28936485
Pathog Immun. 2017;2(3):310-334. doi: 10.20411/pai.v2i3.207. Epub 2017 Aug 02.

BACKGROUND: In HIV infection, lymphoid tissue is disrupted by fibrosis. Angiotensin converting enzyme inhibitors have anti-fibrotic properties. We completed a pilot study to assess whether the addition of lisinopril to antiretroviral therapy (ART) reverses fibrosis of gut tissue, and...

Cite
Cockerham LR, Yukl SA, Harvill K, et al. A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals. Pathog Immun. 2017;2(3):310-334doi: 10.20411/pai.v2i3.207.
Cockerham, L. R., Yukl, S. A., Harvill, K., Somsouk, M., Joshi, S. K., Sinclair, E., Liegler, T., Hoh, R., Lyons, S., Hunt, P. W., Rupert, A., Sereti, I., Morcock, D. R., Rhodes, A., Emson, C., Hellerstein, M. K., Estes, J. D., Lewin, S., Deeks, S. G., & Hatano, H. (2017). A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals. Pathogens & immunity, 2(3), 310-334. https://doi.org/10.20411/pai.v2i3.207
Cockerham, Leslie R, et al. "A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals." Pathogens & immunity vol. 2,3 (2017): 310-334. doi: https://doi.org/10.20411/pai.v2i3.207
Cockerham LR, Yukl SA, Harvill K, Somsouk M, Joshi SK, Sinclair E, Liegler T, Hoh R, Lyons S, Hunt PW, Rupert A, Sereti I, Morcock DR, Rhodes A, Emson C, Hellerstein MK, Estes JD, Lewin S, Deeks SG, Hatano H. A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals. Pathog Immun. 2017;2(3):310-334. doi: 10.20411/pai.v2i3.207. Epub 2017 Aug 02. PMID: 28936485; PMCID: PMC5604865.
Copy Download .nbib Format: NLM
Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies.

Therapeutics and clinical risk management

Bonsu KO, Owusu IK, Buabeng KO, Reidpath DD, Kadirvelu A.
PMID: 27350750
Ther Clin Risk Manag. 2016 Jun 03;12:887-906. doi: 10.2147/TCRM.S106065. eCollection 2016.

Heart failure (HF) is a major public health priority due to its epidemiological transition and the world's aging population. HF is typified by continuous loss of contractile function with reduced, normal, or preserved ejection fraction, elevated vascular resistance, fluid...

Cite
Bonsu KO, Owusu IK, Buabeng KO, et al. Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies. Ther Clin Risk Manag. 2016;12:887-906doi: 10.2147/TCRM.S106065.
Bonsu, K. O., Owusu, I. K., Buabeng, K. O., Reidpath, D. D., & Kadirvelu, A. (2016). Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies. Therapeutics and clinical risk management, 12887-906. https://doi.org/10.2147/TCRM.S106065
Bonsu, Kwadwo Osei, et al. "Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies." Therapeutics and clinical risk management vol. 12 (2016): 887-906. doi: https://doi.org/10.2147/TCRM.S106065
Bonsu KO, Owusu IK, Buabeng KO, Reidpath DD, Kadirvelu A. Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies. Ther Clin Risk Manag. 2016 Jun 03;12:887-906. doi: 10.2147/TCRM.S106065. eCollection 2016. PMID: 27350750; PMCID: PMC4902145.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 1616 entries